Update to unblinding procedures Clarification of randomisation procedures Clarification of drug delivery arrangements Update to the schedule of assessments Update to the case report form completion schedule Clarification of exclusion criteria

Update to the Trial Management Group Clarification of additional embolisation procedures permitted Update to contraception requirements Update to DC Bead loading instructions

Removal of lipase from the eligibility criteria. Addition of Ireland as a participating country (subject to local regulatory and ethical approvals). The units for AFP have changed from ng/ml to kU/L. Therefore, stratification is now (<331, ≥ 331kU/L). Dual Phase CTs are now permitted If a trial participant or partner of a trial participant becomes pregnant, a pregnancy notification form needs to be completed instead of an SAE Form. The first 60 patients are no longer required to complete the debriefing questionnaire to validate the EORTC QLQ-HCC18 questionnaire as validation of this module has now been completed. The insurance section has been modified to comply with UCL’s insurance SOP and updated policy. The primary difference is that patients may be able to claim compensation without the need to prove negligence. Removal of typographical errors.

Changes to the Trial Management Group Exclusion criteria updated to cover patients with prolonged QT/QTC of greater than 450ms Increased ECG monitoring – ECG will now be monitored at each follow up visit, as well as at 72 hours pre-TACE and 7 days post-TACE time points Dose Modifications updated to include discontinuation of sorafenib for patients with QT over 500ms, or 60ms above their baseline reading Appendix 11: Expected Adverse Events updated to reflect additional expected events in line with the current version of the Sorafenib SmPC Appendix 12: Flowchart of Assessments has been revised to include the additional ECGs as earlier indicated

Revised procedure for unblinding patients who have been confirmed locally as having progressive disease

Update to the trial recruitment end date and recruiting centres. Change to end of trial definition and final analysis timelines following futility analysis and trial’s closure to recruitment. Sites allowed to use standard practice of TACE and CT/MRI scans following the trial’s closure to recruitment. End of translational sub-study sample collection. Changes to the process following progression after the trial’s closure to recruitment. Patients will no longer be formally unblinded following progression as all patients have been unblinded following the trial’s closure to recruitment. Details of maintaining the blind and codebreaking removed as no longer necessary. Change to scan schedule to local standard of care and removal of provision of scans to IXICO following the trial’s closure to recruitment. Change to radiological assessments to local standard of care from week 16 onwards Change to the follow up period following the trial’s closure to recruitment. Change to the sorafenib supply and reallocations process. Packs will no longer be allocated and sites will be provided with a supply of unblinded sorafenib. Clarification of the definition of progression in the trial. Changes to DC Bead loading times following advice from manufacturer Biocompatibles. Changes to expected adverse events following review of Sorafenib SpC.